Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Unit · Derivative | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350 Underlying: Common Stock · 5,350 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
GrantStock Option · Derivative | 30,400 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 Underlying: Common Stock · 30,400 shares Expires 2028-02-05 F6 · derivative.exercise_date: Represents option of which 1/48th March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 671 | $83.19 | $55,818.61 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,204 F3 · kind: Sale of 671 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,254) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,375 | $82.98 | $114,095.30 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,950 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:04 UTC |
RASTETTER WILLIAM HDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 20,000 | $7.05 Strike: $7.05 | $141,000.00 |
DisclosureSEC source: 0001209191-18-005543 · doc4.xml · derivative · entry 3 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted May 25, 2011 and vested in 12 equal monthly installments beginning June 25, 2011. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:04 UTC |
RASTETTER WILLIAM HDirector
|
SaleCommon Stock | 9,500 | $90.00 | $855,000.00 |
DisclosureSEC source: 0001209191-18-005543 · doc4.xml · nonDerivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,750 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:04 UTC |
RASTETTER WILLIAM HDirector
|
Exercise / conversionCommon Stock | 20,000 | $7.05 | $141,000.00 |
DisclosureSEC source: 0001209191-18-005543 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:12 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 1,750 | $79.14 | $138,499.03 |
DisclosureSEC source: 0001209191-18-004246 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,723 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.09 to $82.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:10 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,625 | $79.12 | $128,563.01 |
DisclosureSEC source: 0001209191-18-004244 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,316 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.12 to $81.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:09 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,750 | $78.89 | $295,819.88 |
DisclosureSEC source: 0001209191-18-004240 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,357 F1 · kind: Sale of 3,750 shares of common stock issued upon vesting of 7,500 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (3,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.09 to $82.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:07 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,625 | $79.12 | $128,574.71 |
DisclosureSEC source: 0001209191-18-004235 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,226 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.09 to $81.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:08 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,625 | $79.05 | $128,459.50 |
DisclosureSEC source: 0001209191-18-004237 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,871 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.17 to $81.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:57 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003127 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:57 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantNon-Qualified Stock Option · Derivative | 70,000 | $0.00 Strike: $77.81 | $0.00 |
DisclosureSEC source: 0001209191-18-003127 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-08 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 1,979 | $18.15 Strike: $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,789 Underlying: Common Stock · 1,979 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,979 | $79.36 | $157,053.44 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 1,979 | $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:05 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 18,084 | $15.45 Strike: $15.45 | $279,397.80 |
DisclosureSEC source: 0001209191-18-001889 · doc4.xml · derivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,956 Underlying: Common Stock · 18,084 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:05 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 18,084 | $77.52 | $1,401,822.85 |
DisclosureSEC source: 0001209191-18-001889 · doc4.xml · nonDerivative · entry 2 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,017 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.00 to $79.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:05 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionCommon Stock | 18,084 | $15.45 | $279,397.80 |
DisclosureSEC source: 0001209191-18-001889 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,237 | $18.15 Strike: $18.15 | $276,551.55 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,768 Underlying: Common Stock · 15,237 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 15,237 | $75.00 | $1,142,775.00 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 15,237 | $18.15 | $276,551.55 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 2,955 | $18.15 Strike: $18.15 | $53,633.25 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,005 Underlying: Common Stock · 2,955 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4th upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 2,955 | $75.00 | $221,625.00 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 2,955 | $18.15 | $53,633.25 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 6,279 | $18.15 Strike: $18.15 | $113,963.85 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,960 Underlying: Common Stock · 6,279 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 6,279 | $75.04 | $471,159.83 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 6,279 | $18.15 | $113,963.85 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:31 UTC |
LYONS GARY ADirector
|
SaleCommon Stock | 10,000 | $72.92 | $729,182.00 |
DisclosureSEC source: 0001209191-17-063937 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,066 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $70.79 to $73.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:24 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-063918 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:24 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantStock Option · Derivative | 60,000 | $0.00 Strike: $73.60 | $0.00 |
DisclosureSEC source: 0001209191-17-063918 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-12-01 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on December 1, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-qualified Stock Option · Derivative | 9,900 | $18.15 Strike: $18.15 | $179,685.00 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,492 Underlying: Common Stock · 9,900 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/03/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/03/2018. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 9,900 | $73.05 | $723,191.04 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.50 to $73.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 9,900 | $18.15 | $179,685.00 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:15 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 30,000 | $74.58 | $2,237,343.00 |
DisclosureSEC source: 0001209191-17-060286 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,691 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $73.57 to $75.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionNon Qualified Stock Option · Derivative | 7,518 | $8.65 Strike: $8.65 | $65,030.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 7 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,823 Underlying: Common Stock · 7,518 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 14,049 | $8.66 Strike: $8.66 | $121,664.34 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 6 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,049 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionNon Qualified Stock Option · Derivative | 31,250 | $8.66 Strike: $8.66 | $270,625.00 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 5 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,049 Underlying: Common Stock · 31,250 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 7,518 | $69.71 | $524,046.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 4 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionCommon Stock | 7,518 | $8.65 | $65,030.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 45,299 | $69.71 | $3,157,593.97 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionCommon Stock | 45,299 | $8.66 | $392,289.34 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
Exercise / conversionIncentive Stock Option · Derivative | 13,468 | $8.66 Strike: $8.66 | $116,632.88 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,468 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
Exercise / conversionIncentive Stock Option · Derivative | 11,350 | $8.65 Strike: $8.65 | $98,177.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,350 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 13,468 | $71.05 | $956,901.40 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
Exercise / conversionCommon Stock | 13,468 | $8.66 | $116,632.88 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 11,350 | $71.05 | $806,417.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:44 UTC |
Gano KyleChief Business Development Off
|
Exercise / conversionCommon Stock | 11,350 | $8.65 | $98,177.50 |
DisclosureSEC source: 0001209191-17-059430 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 23:14 UTC |
OBrien Christopher FlintChief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 6,925 | $8.65 Strike: $8.65 | $59,901.25 |
DisclosureSEC source: 0001209191-17-055457 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,341 Underlying: Common Stock · 6,925 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 10, 2013 and vested over 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.